Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash & Equivalents (2019 - 2025)

Biodesix's Cash & Equivalents history spans 7 years, with the latest figure at $19.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 27.65% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $19.0 million, down 27.65%, while the annual FY2025 figure was $19.0 million, 27.65% down from the prior year.
  • Cash & Equivalents reached $19.0 million in Q4 2025 per BDSX's latest filing, up from $16.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $56.3 million in Q2 2021 to a low of $11.5 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $28.2 million, with a median of $24.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 660.32% in 2021, then plummeted 70.36% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $32.7 million in 2021, then surged by 31.72% to $43.1 million in 2022, then crashed by 39.0% to $26.3 million in 2023, then decreased by 0.15% to $26.2 million in 2024, then dropped by 27.65% to $19.0 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Cash & Equivalents are $19.0 million (Q4 2025), $16.6 million (Q3 2025), and $20.7 million (Q2 2025).